Cited by 1,233BRCA gene mutations in cancerEpigenetics and DNA MethylationBreast Lesions and Carcinomas

The DOI matches its Crossref record; 39 of the 41 references it cites were found in a registry or an index.

Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors

Esteller, M.·2000·Journal of the National Cancer Institute

Open this paper in CoChat — free account

Abstract

BACKGROUND: Inherited mutations in the BRCA1 gene may be responsible for almost half of inherited breast carcinomas. However, somatic (acquired) mutations in BRCA1 have not been reported, despite frequent loss of heterozygosity (LOH or loss of one copy of the gene) at the BRCA1 locus and loss of BRCA1 protein in tumors. To address whether BRCA1 may be inactivated by pathways other than mutations in sporadic tumors, we analyzed the role of hypermethylation of the gene's promoter region. METHODS: Methylation patterns in the BRCA1 promoter were assessed in breast cancer cell lines, xenografts, and 215 primary breast and ovarian carcinomas by methylation-specific polymerase chain reaction (PCR). BRCA1 RNA expression was determined in cell lines and seven xenografts by reverse transcription-PCR. P values are two-sided. RESULTS: The BRCA1 promoter was found to be unmethylated in all normal tissues and cancer cell lines tested. However, BRCA1 promoter hypermethylation was present in two breast cancer xenografts, both of which had loss of the BRCA1 transcript. BRCA1 promoter hypermethylation was present in 11 (13%) of 84 unselected primary breast carcinomas. BRCA1 methylation was strikingly associated with the medullary (67% methylated; P =.0002 versus ductal) and mucinous (55% methylated; P =.0033 versus ductal) subtypes, which are overrepresented in BRCA1 families. In a second series of 66 ductal breast tumors informative for LOH, nine (20%) of 45 tumors with LOH had BRCA1 hypermethylation, while one (5%) of 21 without LOH was methylated (P =.15). In ovarian neoplasms, BRCA1 methylation was found only in tumors with LOH, four (31%) of 13 versus none of 18 without LOH (P =.02). The BRCA1 promoter was unmethylated in other tumor types. CONCLUSION: Silencing of the BRCA1 gene by promoter hypermethylation occurs in primary breast and ovarian carcinomas, especially in the presence of LOH and in specific histopathologic subgroups. These findings support a role for this tumor suppressor gene in sporadic breast and ovarian tumorigenesis.

Integrity signals

Registry

Crossref · 10.1093/jnci/92.7.564

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,634
Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J., Lee, M. K., Newman, B. M., Morrow, J. E., Anderson, L. A., Huey, B., & King, M. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,544
Cancer-epigenetics comes of age
Jones, P. A., & Laird, P. W. (1999) · Nature Genetics · doi:10.1038/5947 · Cited by 2,358
Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia
Baylln, S. B., Herman, J. G., Graff, J. R., Vertino, P. M., & Issa, J. J. (1997) · Advances in cancer research · doi:10.1016/s0065-230x(08)60702-2 · Cited by 1,919
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
Herman, J. G., Umar, A., Polyák, K., Graff, J. R., Ahuja, N., Issa, J. J., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., Kinzler, K. W., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6870 · Cited by 1,887
Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines.
Kane, M., Loda, M. F., Gaida, G. M., Lipman, J., Mishra, R., Goldman, H., Jessup, J. M., & Kolodner, R. D. (1997) · PubMed · Cited by 1,476
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.
Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B., & Herman, J. G. (1999) · PubMed · Cited by 1,253
Self-citation
Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families
Friedman, L. S., Ostermeyer, E. A., Szabo, C. I., Dowd, P., Lynch, E. D., Rowell, S. E., & King, M. (1994) · Nature Genetics · doi:10.1038/ng1294-399 · Cited by 622
Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression
Thompson, M. E., Jensen, R. A., Obermiller, P. S., Page, D. L., & Holt, J. T. (1995) · Nature Genetics · doi:10.1038/ng0495-444 · Cited by 584

Show all 41 references

Sorted by citations

Items 801–900 of 1,000

Classification of ovarian carcinomas based on pathology and molecular genetics
D′Angelo, E., & Prat, J. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0599-0 · Cited by 11
The Future of Epigenetics: Emerging Technologies and Clinical Applications
Iyer, K. A., Tenchov, R., Sasso, J. M., Thite, T., Deng, Y., & Zhou, Q. A. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00729 · Cited by 12
DNA methyltransferase inhibitors in oncology: clinical progress, limitations and future directions
Michael, D. C., & Mehdipour, P. (2026) · Epigenomics · doi:10.1080/17501911.2026.2637418 · Cited by 12
“The promoters of TSGs such as CDKN2A /p16INK4a [208], BRCA1 [61] and CDH1 [209] are often aberrantly hypermethylated, leading to their transcriptional silencing in cancers.”
Epigenetic targets to enhance antitumor immune response through the induction of tertiary lymphoid structures
Omotesho, Q. A., Escamilla, A., Pérez-Ruiz, E., Frecha, C. A., Rueda‐Domínguez, A., & Barragán, I. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1348156 · Cited by 10
A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol
Nicum, S., Roberts, C., Boyle, L., Kopijasz, S., Gourley, C., Hall, M., Montes, A., Poole, C. J., Collins, L., Schuh, A., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-983 · Cited by 10
“In addition to germline BRCA1/2 mutations, silencing of BRCA1/2 expression can also occur via epigenetic processes such as promoter hyper- methylation and this has been documented in 11-14% of breast cancers [2] and 11-35% of ovarian cancer patients [3].”
epialleleR: an R/Bioconductor package for sensitive allele-specific methylation analysis in NGS data
Nikolaienko, O., Lønning, P. E., & Knappskog, S. (2022) · GigaScience · doi:10.1093/gigascience/giad087 · Cited by 10
Epigenetic Biomarkers and Breast Cancer: Cause for Optimism
Visvanathan, K., Sukumar, S. V., & Davidson, N. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2001 · Cited by 10
Critical role for BRCA1 expression as a marker of chemosensitivity response and prognosis
Siervi, A. D. (2015) · Frontiers in Bioscience-Elite · doi:10.2741/752 · Cited by 18
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer
Manzo, J., Puhalla, S., Pahuja, S., Ding, F., Lin, Y., Appleman, L. J., Tawbi, H. A.-H., Stoller, R. G., Lee, J. J., Diergaarde, B. B., et al. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04430-6 · Cited by 10
BRCA2 Promoter Hypermethylation in Sporadic Breast Cancer
Bosviel, R., Durif, J., Guo, J., Mebrek, M., Kwiatkowski, F., Bignon, Y., & Bernard-Gallon, D. J. (2012) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2012.0060 · Cited by 10
“Epigenetic modifications such as promoter hypermethylation of the oncosuppressor genes BRCA1 and BRCA2 can play a role in the oncogenesis of cancer (Esteller et al., 2000).”
Breast cancer gene discovery
Polyák, K. (2002) · Expert Reviews in Molecular Medicine · doi:10.1017/s146239940200491x · Cited by 10
Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients
Hosny, M. M., Sabek, N. A., El-Abaseri, T. B., Hassan, F., & Farrag, S. H. (2016) · International Journal of Breast Cancer · doi:10.1155/2016/9545241 · Cited by 10
“Although most published studies mentioned above [15, 19, 36, 37] used MSP, the primer sequences and target regions varied from study to study.”
Bioelectrochemistry of nucleic acids for early cancer diagnostics – analysis of DNA methylation and detection of microRNAs
Bartošík, M., & Hrstka, R. (2016) · Reviews in Analytical Chemistry · doi:10.1515/revac-2016-0022 · Cited by 10
“1998), BRCA1 (Esteller et al.”
Methylation synthetic lethality: Exploiting selective drug targets for cancer therapy
Ye, B.-J., Li, D.-F., Li, X., Hao, J.-L., Liu, D.-J., Yu, H., & Zhang, C. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217010 · Cited by 9
Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines
Dodson, A. E., Shenker, S., Sullivan, P., Nayak, S. U., Middleton, C., McGuire, M. S., Chipumuro, E., Mishina, Y., Tobin, E. R., Cadzow, L., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0316 · Cited by 9
“Given the constraints of genetic testing, alternative HRD detection Another approach for detecting HRD assesses the mutational footprints, or genomic “scars,” characteristic of HRD tumors.”
Applications of CRISPR-Cas9 in mitigating cellular senescence and age-related disease progression
Azani, A., Sharafi, M., Doachi, R., Akbarzadeh, S., Lorestani, P., Olia, A. H. K., Zahed, Z., Gharedaghi, H., Ghasrsaz, H., Foroozand, H., et al. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01771-3 · Cited by 9
“Several BC genes show CpG island hypermethylation or aberrant promoter methylation, leading to silencing of tumor-suppressor genes involved in estrogen signaling, apoptosis, cell cycle, and DNA repair, such as HOXA5, TMS1, p16, RASSF1A, BRCA, E-cadherin, GSTP1, and p21/CIP1/WAF1 [69–75].”
Assessment of Homologous Recombination Deficiency in Ovarian Cancer
Garg, V., & Oza, A. M. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0563 · Cited by 9
BRCA1 as a tumor suppressor linked to the regulation of epigenetic states: keeping oncomiRs under control
Stefánsson, Ó. A., & Esteller, M. (2012) · Breast Cancer Research · doi:10.1186/bcr3119 · Cited by 9
“In sporadic cases of breast cancer, however, the BRCA1 gene is inactivated by epigenetic mechanisms [12,13] rather than by acquired point mutations [14].”
BackgroundSelf-citation
A 2015 survey of established or potential epigenetic biomarkers for the accurate detection of human cancers
Amacher, D. E. (2016) · Biomarkers · doi:10.3109/1354750x.2016.1153724 · Cited by 9
“Conversely, the silencing of the BRCA1 gene via promoter hypermethylation has been reported in sporadic breast and ovarian tumorigenesis (Esteller et al., 2000).”
Background
Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma
Zhen, D. B., Coveler, A. L., Zanon, S. M., Reni, M., & Chiorean, E. G. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.05.004 · Cited by 9
MicroRNA‑126 expression in the peripheral white blood cells of patients with breast and ovarian cancer is a potential biomarker for the early prediction of cancer risk in the carriers of methylated BRCA1
Al‐Showimi, M., Al‐Yousef, N., Alharbi, W., Alkhezayem, S., Almalik, O., Alhusaini, H., Alghamdi, A. A., & Al‐Moghrabi, N. (2022) · Oncology Letters · doi:10.3892/ol.2022.13396 · Cited by 9
Epigenetic factors in breast cancer therapy
Mathur, R., Jha, N. K., Saini, G., Jha, S. K., Shukla, S. P., Filipejová, Z., Kesari, K. K., Iqbal, D., Nand, P., Upadhye, V. J., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.886487 · Cited by 13
c-Jun N-terminal kinase 2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting p53/Notch1 and breast cancer gene 1 expression
Cantrell, M. A., Ebelt, N. D., Pfefferle, A. D., Perou, C. M., & Berg, C. L. V. D. (2015) · Oncotarget · doi:10.18632/oncotarget.3787 · Cited by 9
“Aside from hereditary breast cancer, low BRCA1 expression occurs in sporadic breast cancers by means of promoter methylation or overexpression of transcriptional repressors [15, 16].”
Background
SVEP1 promoter regulation by methylation of CpG sites
Glait‐Santar, C., & Benayahu, D. (2011) · Gene · doi:10.1016/j.gene.2011.09.012 · Cited by 9
Molecular Screening of Cancer
Srivastava, S. (2006) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256460 · Cited by 9
Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer
Romeo, M., Pardo, J. C., Martínez‐Cardús, A., Martinez‐Balibrea, E., Quiroga, V., Martínez‐Román, S., Solé, F. G., Vila, M. M., & Mesı́a, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103249 · Cited by 10
“However, the most frequent event causing BRCA1 inactivation in sporadic HGSOC is its promoter hypermethylation (~15%) [5].”
Background
The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents
Kim, G., Kim, J., Han, S., Hwang, I. K., Kim, H. J., & Min, H. (2019) · Oncology Letters · doi:10.3892/ol.2019.10169 · Cited by 9
“The decrease or loss of BRCA1 expression can be explained by a mutation of the BRCA1 gene, BRCA1 promoter hypermethylation, or overexpression of microRNAs that target BRCA1 mRNA (8-12).”
Background
Strategies for the detection of site-specific DNA methylation and its application, opportunities and challenges in the field of electrochemical biosensors
Ye, C.-L., Zhao, Z., Lai, P., Chen, C., Jian, F., Liang, H., & Guo, Q. (2024) · Analytical Methods · doi:10.1039/d4ay00779d · Cited by 8
BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitors
Däster, K., Hench, J., Diepenbruck, M., Volkmann, K., Rouchon, A., Palafox, M., Miragaya, J. G., Preca, B., Kurzeder, C., Weber, W. P., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07502-8 · Cited by 8
Validation and Performance of Quantitative BRCA1 and RAD51C Promoter Hypermethylation Testing in Breast and Ovarian Cancers
Fink, J. L., Jaradi, B., Stone, N., Sanker, B., Zhang, F., Dobrovic, A., Kirschner, S. A., Hadfield, J., Kondrashova, O., & Waring, P. (2024) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2024.11.004 · Cited by 9
Detecting Rare Mutations Associated with Cancer Risk
Wilson, V. L. (2001) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200101040-00005 · Cited by 8
Cancer du sein chez l’homme au Maroc : épidémiologie et facteurs pronostiques. À propos de 140 cas
Slimani, K. A., Debbagh, A., Sbitti, Y., Errihani, H. H., & Ichou, M. (2016) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2016.08.009 · Cited by 8
Genetics and Epigenetics in Tumorigenesis: Acting Separately or Linked?
Zhu, X., Wetta, H., & Zhu, X. (2014) · Cited by 8
Targeting homologous recombination repair in cancer
Murfuni, I., & Rass, U. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803582-5.00008-5 · Cited by 8
Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients
Rodríguez-Balada, M., Roig, B., Melé, M., Salvat, M., Martorell, L., Borràs, J., & Gumà, J. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1837-0 · Cited by 8
“This epigenetic process has been well-described as a somatic event mainly as a second hit, specifically in breast tumors [2].”
Background
BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma
Abdallah, R., Zhao, S., Garinet, S., Hormigos, K., Corre, D. L., Cros, J. F., Perez‐Toralla, K., Bats, A., Augustin, J., Bachet, J., et al. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.101880 · Cited by 8
Methylation of promoter region of BRCA1 gene versus pathogenic variants of gene: risk factor or clinical marker of breast cancer
Lobanova, O., Medvedieva, N., Fishchuk, L., Dubitska, O., Cheshuk, V., Vereshchako, R., Захарцева, Л. М., Rossokha, Z. I., & Горовенко, Н. Г. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06774-2 · Cited by 8
“It is known that hypermethylation of the BRCA1 promoter is more common in sporadic breast cancer, and in our study we found a similar trend (not confirmed by statistical results) for tumor tissue samples but not peripheral blood samples in the BC patients [68].”
Result
Targeting BRCA‐mutant biliary tract cancer: Current evidence and future perspectives
Li, X. Y., Chen, J. Q., Aisa, A., Ding, Y. W., Zhang, D., & Yuan, Y. (2023) · Journal of Digestive Diseases · doi:10.1111/1751-2980.13168 · Cited by 8
“It has been found that promoter hypermethylation silences the BRCA gene in breast and ovarian cancers, suggesting that focusing solely on mutation may leave out certain individuals who may benefit from targeted therapy.(86,87) A patient with CpG island hypermethylation in the BRCA promoter and a poor prognosis was tak…”
Background
BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells.
Horiuchi, A., Wang, C., Kikuchi, N., Osada, R., Nikaido, T., & Konishi, I. (2007) · PubMed Central · Cited by 8
DNA Methylation and Cancer
Neidhart, M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-420194-1.00007-5 · Cited by 9
Epigenetics as the Underlying Mechanism for Monozygotic Twin Discordance
Hogenson, T. L. (2013) · Medical Epigenetics · doi:10.1159/000353688 · Cited by 9
Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer
Schaule, J., Geeleher, P., Zuo, Z., Weichselbaum, R. R., Vokes, E. E., Fetscher, S., & Seiwert, T. Y. (2014) · Oral Oncology · doi:10.1016/j.oraloncology.2014.06.004 · Cited by 8
“Several mechanisms have been found to contribute to the HRD phenotype, such as silencing of BRCA2 by EMSY [13], downregulation of BRCA1 by the transcription factor ETS-1 [14], or hypermethylation of the BRCA1 promoter [15].”
Background
Induction of the long noncoding RNA NBR2 from the bidirectional BRCA1 promoter under hypoxic conditions
Wiedmeier, J. E., Ohlrich, A., Chu, A., Rountree, M. R., & Turker, M. S. (2017) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2017.02.001 · Cited by 8
Review of biomarker systems as an alternative for early diagnosis of ovarian carcinoma
Srivastava, A., Gupta, A., & Patidar, S. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02604-x · Cited by 8
“It is an established fact, in accordance with Esteller M [12], that in most forms of carcinoma, DNA promoter hypermethylation of TSG occurs which represses TSG and results in the formation of the tumors.”
Result
Author reply
Keen, J. C., & Davidson, N. E. (2003) · Cancer · doi:10.1002/cncr.11592 · Cited by 8
BRCA1 and Estrogen Receptor α Expression Regulation in Breast Cancer Cells
Scherbakov, A. M., Shestakova, E. A., Галеева, К. Э., & Богуш, Т. А. (2019) · Molecular Biology · doi:10.1134/s0026893319030166 · Cited by 8
Genetic and epigenetic characterization of the BRCA1 gene in Brazilian women at-risk for hereditary breast cancer
Felicio, P. S., Melendez, M. E., Arantes, L. M. R. B., Kerr, L. M., Carraro, D. M., Grasel, R. S., Campacci, N., Scapulatempo‐Neto, C., Fernandes, G. C., de Carvalho, A. C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13750 · Cited by 8
Tumor Suppressor Genes
Lü, Z., & Bast, R. C. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-98094-2_5 · Cited by 8
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk: A Perspective
Dobrovic, A. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3340 · Cited by 8
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial
Azaïs, H., Brochard, C., Taly, V., Benoit, L., Ferron, G., Ray-Coquard, I. L., You, B., Abadie‐Lacourtoisie, S., Lebreton, C., Venat, L., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.12.004 · Cited by 7
Ovarian Carcinomas
Prat, J., D′Angelo, E., & Espinosa, Í. (2025) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002352 · Cited by 7
“29 Homologous recombination de ﬁ ciency (HRD) resulting from genetic or epigenetic inactivation of the DNA double-strand break repair genes, such as BRCA1/2 , occurs in ∼ 50% of HGSCs. 26 This high frequency of genetic and/or epigenetic alterations in the DNA repair genes may explain the high…”
The Role of Somatic Mutation in Hereditary Hemorrhagic Telangiectasia Pathogenesis
DeBose-Scarlett, E. M., & Marchuk, D. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134479 · Cited by 7
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study
Gounder, M. M., Schöffski, P., Jones, R. L., Stacchiotti, S., Demetri, G. D., Cote, G. M., Agulnik, M., Chugh, R. K., Jahan, T. M., Gupta, A. A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69708-2 · Cited by 7
“The Independent Ethics Committee or Institutional Review Board at each participating site approved the protocol (Supplementary Note 3).”
Influential
Breast Cancer Epigenetics
Pitta, C. A., & Constantinou, A. I. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800206-3.00010-0 · Cited by 7
Evaluation of promoter hypermethylation of tumor suppressor gene BRCA1 in epithelial ovarian cancer
Das, J., Chandra, L., Gandhi, G., Amle, D. B., Patnayak, R. L., Khurana, N., & Saxena, A. (2021) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_390_20 · Cited by 7
Isolation and Quantification of Methylated Cell-Free DNA in Plasma on an Integrated Microfluidic System
Cheng, Y., Wang, C., Hsu, K., & Lee, G. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c04471 · Cited by 7
The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets
Yang, G., Lü, T., Weisenberger, D. J., & Liang, G. (2022) · Genes · doi:10.3390/genes13091555 · Cited by 7
Alteration of DNA Methyltransferases by Eribulin Elicits Broad DNA Methylation Changes with Potential Therapeutic Implications for Triple-Negative Breast Cancer
Bagheri, M., Lee, M. K., Muller, K. E., Miller, T. W., Pattabiraman, D. R., & Christensen, B. C. (2024) · Epigenomics · doi:10.2217/epi-2023-0339 · Cited by 7
Depletion of eIF2.GTP.Met-tRNAi translation initiation complex up-regulates BRCA1 expressionin vitroandin vivo
Aktas, B. H., Bordelois, P., Peker, S., Merajver, S., & Halperin, J. A. (2015) · Oncotarget · doi:10.18632/oncotarget.3125 · Cited by 7
“Consistently, most breast and ovarian cancers express low, sometimes undetectable, levels of BRCA1 [6, 7].”
Background
La cancérogenèse ovarienne : théories actuelles et passées
Chêne, G., Penault-Llorca, F. M., Raoelfils, I., Bignon, Y., Ray-Coquard, I., SEFFERT, P., & Dauplat, J. (2011) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2011.02.010 · Cited by 7
Primary Squamous Cell Carcinoma of the Endometrium Unrelated to Human Papilloma Virus: A Molecular Study
Giordano, G., Pizzi, S., Azzoni, C., Bottarelli, L., & D’Adda, T. (2013) · Pathology & Oncology Research · doi:10.1007/s12253-013-9607-3 · Cited by 7
“Hyper-methylation of the BRCA1 promoter has been detected in sporadic breast [40] and ovarian cancer samples [32, 41].”
The Culturable Microbial and Chemical Qualities of Some Waters Used for Drinking and Domestic Purposes in a Typical Rural Setting of Southwestern Nigeria
Okoh, A. I., Bakare, M. K., Okoh, O. O., & ., E. O. (2005) · Journal of Applied Sciences · doi:10.3923/jas.2005.1041.1048 · Cited by 7
Epigenetic markers in human gliomas: prospects for therapeutic intervention
Hesson, L. B., Krex, D., & Latif, F. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.10.1475 · Cited by 7
Techniques to Study DNA Methylation and Histone Modification
Lara, E., Calvanese, V., Fernández, A. F., & Fraga, M. F. (2011) · Springer eBooks · doi:10.1007/978-1-84882-644-1_2 · Cited by 7
Conference on Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer Progression
McGee, S. F., Lanigan, F. T., Gilligan, E., & Groner, B. (2006) · Cited by 7
Cancer Epigenetics
Takeshima, H., Yamada, H., & Ushijima, T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00005-3 · Cited by 7
Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets
Zambelli, A., Sgarra, R., Sanctis, R. D., Agostinetto, E., Santoro, A., & Manfioletti, G. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2084380 · Cited by 7
“(DNA methyltransferase inhibitors) and the histone deacetylase (HDAC) inhibitors [126,127].”
Background
BRCA1 in initiation, invasion, and metastasis of breast cancer: a perspective from the tumor microenvironment
McCullough, S. D., Hu, Y., & Li, R. (2007) · Cancer metastasis · doi:10.1007/978-1-4020-5867-7_3 · Cited by 7
Genetische Risikofaktoren des Mammakarzinoms
Beckmann, M., Fasching, P. A., Gall, C. M., Bani, M., Brumm, C., & Krämer, S. (2002) · Der Gynäkologe · doi:10.1007/s00129-002-1193-5 · Cited by 7
Targeted therapies in gynecologic cancers and melanoma
Ortega, E., Marti, R. M., Yeramian, A., Sorolla, A., Dolcet, X., Llobet‐Navàs, D., Abal, L., Santacana, M., Pallarés, J., Llombart‐Cussac, A., et al. (2008) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2008.07.008 · Cited by 7
Establishment and characterisation of two novel breast cancer cell lines
Bagadi, S. A. R., Kaur, J., & Ralhan, R. (2007) · Cell Biology International · doi:10.1016/j.cellbi.2007.08.010 · Cited by 7
“tumours (Catteau et al., 1999; Esteller et al., 2000; Matros et al., 2005) and in a parallel study in primary breast tumours in the author’s laboratory (data not shown).”
Background
Erratum to: Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Oaknin, A., Guarch, R., Barretina-Ginesta, M.-P., Hardisson, D., González-Martı́n, A., Matías‐Guiu, X., Fidalgo, J. A. P., Vieites, B., Romero, I., & Palacios, J. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1746-7 · Cited by 7
Glyphosate-based herbicide as a potential risk factor for breast cancer
Alves, L. N. R., Merigueti, L. P., Casotti, M. C., de Araújo, B. C., Trabach, R. S. D. R., Batitucci, M. D. C. P., Meira, D. D., Paula, F., dos Santos, E. D. V. W., & Louro, I. D. (2025) · Food and Chemical Toxicology · doi:10.1016/j.fct.2025.115404 · Cited by 6
Beyond Structure: Methylation Fine‐Tunes Stability and Folding Kinetics of bcl2Mid G‐Quadruplex
Medved, N., Cevec, M., Javornik, U., Lah, J., Hadži, S., & Plavec, J. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202507544 · Cited by 7
Epigenetic Regulation of DLK1-DIO3 Region in Thyroid Carcinoma
Alves, L. F., da Silva, I. N., de Mello, D. C., Fuziwara, C. S., Guil, S., Esteller, M., & Geraldo, M. V. (2024) · Cells · doi:10.3390/cells13121001 · Cited by 6
“Global hypomethylation, together with the focal hypermethylation of regulatory elements associated with CGIs, is constantly seen in cancer [34].”
BackgroundSelf-citation
High frequency of BRCA1/2 and p53 somatic inactivation in sporadic ovarian cancer
Zikán, M., Janatová, M., Pavlista, D., & Pohlreich, P. (2007) · Journal of Genetics · doi:10.1007/s12041-007-0022-y · Cited by 6
“Other possible means of somatic inactivation of BRCA genes have been described: occasionally through gross genomic rearrangements, but most commonly by hypermethylation of promotor sequences or related (or independent) reduced expression of BRCA genes (Esteller et al. 2000; Miyamoto et al. 2002).”
Background
Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer
Shen, Y. T., Wang, L. L., Evans, J. C., Allen, C. J., & Piquette‐Miller, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102498 · Cited by 6
“While the reason for this discrepancy remains unknown, similar findings have been previously reported in breast cancer cell lines where increased methylation at the BRCA1 promoter was observed after inoculation into immunodeficient mice [37].”
Result
Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer
Zhou, C., Porter, N. R., Borges, M. W., Gauthier, C. D., Ferguson, L. G., Huang, B., Nanda, N., He, J. P., Laheru, D. A., Hruban, R. H., et al. (2021) · Pancreatology · doi:10.1016/j.pan.2021.03.015 · Cited by 5
Expression Profiling in Ovarian Cancer Reveals Coordinated Regulation of BRCA1/2 and Homologous Recombination Genes
Custódio, N., Savisaar, R., Carvalho, C., Bak‐Gordon, P., Ribeiro, M. I., Tavares, J., Borralho, P., Peixoto, A., Pinto, C., Escudeiro, C., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020199 · Cited by 6
“A possible cause for such a reduction could be epigenetic silencing via promoter hypermethylation, which has been detected in the BRCA1 gene in 10–20% of ovarian cancers [13,38,39].”
Background
DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer
Ebata, T., Yamashita, S., Takeshima, H., Yoshida, H., Kawata, Y., Kino, N., Yasugi, T., Terao, Y., Yonemori, K., Kato, T., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.10.008 · Cited by 6
BRCA1 promoter methylation & its immunohistochemical correlation in sporadic breast cancer
Khan, F., Agarwal, P., Gupta, S., Maurya, M. K., Singh, P., Agarwal, A., Singh, K., Sonkar, A. A., & Goel, M. M. (2023) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_4605_20 · Cited by 6
Mass Spectrometry-Based Proteomics: Analyses Related to Drug-Resistance and Disease Biomarkers
Agostini, M., Traldi, P., & Hamdan, M. H. (2023) · Medicina · doi:10.3390/medicina59101722 · Cited by 6
“Another study reported the silence of the DNA repair gene (BRCA1) in For instance, retinoblastoma tumor suppressor (RB1) was identified as one of the suppressor genes that hypermethylated in tumor tissues [56]. breast and ovarian cancers due to its hypermethylation [57].”
Background
Targeting Triple-Negative Breast Cancer and High-Grade Ovarian Carcinoma: Refining BRCAness Beyond BRCA1/2 Mutations?
Jacot, W., Theillet, C. G., Guiu, S., & Lamy, P. (2015) · Future Oncology · doi:10.2217/fon.14.268 · Cited by 6
Hypermethylation of BRCA1 Gene in Meningioma in Elderly Males
Lombardi, I. A. S., FARIA, M. H. G., Rabenhorst, S. H. B., Zanini, M. A., Pardini, M. I. D. M. C., Grotto, R. M. T., & Ferrasi, A. C. (2018) · Anticancer Research · doi:10.21873/anticanres.12526 · Cited by 6
Cancer Epigenetics
Riley, L. B., & Anderson, D. W. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-375709-8.00032-0 · Cited by 8
Identifying the BRCA1 c.-107A > T variant in Dutch patients with a tumor BRCA1 promoter hypermethylation
de Jong, V. M. T., Pruntel, R., Steenbruggen, T. G., Bleeker, F. E., Nederlof, P. M., Hogervorst, F. B. L., & Linn, S. C. (2022) · Familial Cancer · doi:10.1007/s10689-022-00314-z · Cited by 6
Transcriptional Profiling of Breast Cancer Cells Exposed to Soy Phytoestrogens After BRCA1 Knockdown With a Whole Human Genome Microarray Approach
Satih, S., Chalabi, N., Rabiau, N., Bignon, Y., & Bernard-Gallon, D. J. (2010) · Nutrition and Cancer · doi:10.1080/01635581003605540 · Cited by 6
“In addition, because BRCA1 expression is often decreased in sporadic breast cancer, an abnormal BRCA1 expression may also play a role ( 3 – 5 ).”
Background
BRCA1: A locus‐specific “liaison” in gene expression and genetic integrity
Aiyar, S. E., Sun, J., & Li, R. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20386 · Cited by 6
“Moreover, the promoter of the BRCA1 gene is hypermethylated in 10%–15% of sporadic breast and ovarian cancer cases [Catteau et al., 1999; Esteller et al., 2000; Magdinier et al., 2000], further supporting the notion that BRCA1 may also play a role in suppression of sporadic breast cancer.”
Background
Loss of Heterozygosity Analysis in Ductal Lavage Samples from BRCA1 and BRCA2 Carriers: A Cautionary Tale
Antill, Y. C., Mitchell, G., Johnson, S. A. S., Devereux, L., Milner, A. D., Phillips, K., & Campbell, I. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0986 · Cited by 6
“(Cancer Epidemiol Biomarkers Prev 2006;15(7):1396–8)”
Background
Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasmsPreprint
Castillo, S. C., Montibus, B., Rocha, A. V., Duke, W., von Meyenn, F., McLornan, D. P., Harrison, C. N., Mullally, A., Schulz, R., & Oakey, R. J. (2021) · Genome Research · doi:10.1101/gr.270066.120 · Cited by 6
“2020), repression of expression by DNA methylation at CGI-associated promoters is a hallmark of cancer (Esteller et al. 2000).”
Background
Breast Cancer Disparities in African and African-Ancestry Populations: Genetics, Epigenetics, Structural Barriers and Technology-Enabled Solutions
Eze, C., Swadi, R., Ross, K., & Sharma, V. (2026) · British Journal of Biomedical Science · doi:10.3389/bjbs.2026.16013 · Cited by 5
“Hypermethylation of the promoter region of the BRCA1 promoter region, effectively silences its expression without altering the underlying DNA sequence [22, 23].”
Promoter Hypermethylation of the BRCA1 Gene as a Novel Biomarker for Prostate Cancer
Saleem, M. A., & Mustafa, M. S. (2024) · Cureus · doi:10.7759/cureus.66467 · Cited by 5
“These primers have undergone extensive characterization by previous research groups [27-29].”
Background
High prevalence of constitutional BRCA1 epimutation in patients with early-onset triple-negative breast cancer
Schwartz, M., Ibadioune, S., Delhomelle, H., Barraud, S., Caputo, S. M., Trabelsi‐Grati, O., Villy, M., Laugé, A., Tang, R., Rouleau, É., et al. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01885-1 · Cited by 5
Antitumor Activity of Indole-3-carbinol in Breast Cancer Cells: Phenotype, Genetic Pattern, and DNA Methylation Inversion
Poloznikov, A. A., Muyzhnek, E., Nikulin, S. V., Каприн, А. Д., Ashrafyan, L. А., Ni, R., Гаджимурадовна, Л. П., & Kiselev, V. I. (2020) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683820090070 · Cited by 5
From multi-omics integration towards novel genomic interaction networks to identify key cancer cell line characteristics
Kuijpers, T., Kleinjans, J. C. S., & Jennen, D. G. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-90047-3 · Cited by 5
An Optimized CoBRA Method for the Microfluidic Electrophoresis Detection of Breast Cancer Associated RASSF1 Methylation
Aibel, C., Peña, A. C. D., & Tripathi, A. (2023) · BioTech · doi:10.3390/biotech12010007 · Cited by 5
DNA damage response-related immune activation signature predicts the response to immune checkpoint inhibitors: from gastrointestinal cancer analysis to pan-cancer validation
Yan, J., Wang, S., Zhang, J., Yuan, Q., Gao, X., Zhang, N., Pan, Y., Zhang, H., Liu, K., Yu, J., et al. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0303 · Cited by 5
Exploring the Advantages and Limitations of CRISPR-Cas in Breast Cancer
Rangel, N., Camargo, V., Castellanos, G., Forero‐Castro, M., & Rondón‐Lagos, M. (2024) · Gene Expression · doi:10.14218/ge.2023.00154 · Cited by 7
Pamiparib as consolidation treatment after concurrent chemoradiotherapy of limited-stage small cell lung cancer: a single-arm, open-label phase 2 trial
Mao, J., Ni, J., Chu, L., Chu, X., Xu, D., Yang, X., & Zhu, Z. (2024) · Radiation Oncology · doi:10.1186/s13014-024-02437-2 · Cited by 5
“Secondly, despite SCLC tumors naturally having the ability for homologous recombination (HR), preclinical data still strongly indicate their remarkable responsiveness to PARPi [14, 15].”
Background
An update on existing therapeutic options and status of novel anti-metastatic agents in breast cancer: Elucidating the molecular mechanisms underlying the pleiotropic action of Withania somnifera (Indian ginseng) in breast cancer attenuation
Srivastava, A., Ahmad, R., Yadav, K., Siddiqui, S., Trivedi, A., Misra, A., Mehrotra, S., Ahmad, B., & Khan, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112232 · Cited by 6

Authors: Esteller, M.
Affiliations: Roswell Park Comprehensive Cancer Center (US)
Corresponding author: Esteller, M.
ORCID: Esteller, M.
Venue: Journal of the National Cancer Institute
Publisher: Oxford University Press (OUP)
Published: 2000-04-05
Volume: 92
Issue: 7
Pages: 564-569
ISSN: 0027-8874 (ISSN-L)
1460-2105
DOI: 10.1093/jnci/92.7.564
OpenAlex: W2160234594
Cited by: 1,233
References: 41
Citations by year: 2026: 20 · 2025: 33 · 2024: 37 · 2023: 46 · 2022: 49 · 2021: 40 · 2020: 53 · 2019: 43 · 2018: 60 · 2017: 48 · 2016: 52 · 2015: 69 · 2014: 56 · 2013: 57 · 2012: 69
FWCI: 22.63
Type: journal article
Language: en
Open access: closed
Locations: JNCI Journal of the National Cancer Institute (publishedVersion)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Funders: National Cancer Institute (R01CA043318, CA 43318)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
Keywords: BRCA1 promoter hypermethylation, sporadic breast cancer, ovarian cancer, loss of heterozygosity, gene silencing, tumor suppressor, medullary breast carcinoma, mucinous breast carcinoma, histological subtypes, epigenetic silencing, breast cancer xenografts
MeSH terms: Breast Neoplasms, Female, Humans, Methylation, Ovarian Neoplasms, Promoter Regions, Genetic, RNA, RNA, Neoplasm, Transplantation, Heterologous, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Carcinoma, Ductal, Breast, Genes, BRCA1, Loss of Heterozygosity, Reverse Transcriptase Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks